We previously reported that single nucleotide polymorphism (SNP)-420 C.G (rs1862513) in the promoter region of RETN was associated with type 2 diabetes. Plasma resistin was tightly correlated with SNP-420 genotypes. SNP-420 is a CpG-SNP affecting the sequence of cytosinephosphate-guanine dinucleotides.
R esistin, which antagonizes the action of insulin, is a cytokine secreted from adipocytes in mice (1) . In humans, resistin is mainly expressed in macrophages and monocytes (2) . We previously reported that single nucleotide polymorphism (SNP) at -420 [SNP-420 (rs1862513)], located in the promoter region of the human resistin gene (RETN), was associated with type 2 diabetes (T2D) (3) . The G/G genotype at SNP-420 increased T2D susceptibility by enhancing its promoter activity through the specific binding of Sp1/3 transcription factors (3) (4) (5) . Plasma resistin was highly regulated by the genotype of SNP-420 in the Japanese population. Plasma resistin was found to be highest in the G/G genotype, followed by C/G, and C/C (4) . An A at -358 [SNP-358 (rs3219175)], which is also located in the promoter region of RETN, is required for a G at SNP-420 to confer the highest plasma resistin in the general Japanese population (6, 7) .
We also reported that plasma resistin was correlated with insulin resistance, low serum HDL cholesterol, and high highly sensitive C-reactive protein (hs-CRP) in the Japanese general population (4) . Elevated resistin predicted the presence and severity of coronary artery disease in healthy subjects (8) . Plasma resistin was increased in presence of the metabolic syndrome, and was positively associated with increased cardiovascular risk (9) . Higher circulating resistin could be associated with metabolic syndrome and atherosclerosis through insulin resistance (10) (11) (12) .
It remains controversial as to whether circulating resistin or SNP-420 is associated with insulin resistance or T2D in humans (13) (14) (15) . An increased risk of developing T2D was observed in American subjects with elevated serum resistin in the case-control study (14) . It was also reported that G/G genotype at SNP-420 was a predictor of glycemic progression in Chinese population in the 5-year prospective study (16) . In contrast, a number of previous genome-wide association studies have not identified RETN SNP-420 as a locus that is susceptible to T2D. Factors such as epigenetic effects and ethnic difference in genome could explain this discrepancy (6) .
DNA methylation is 1 of the epigenetic mechanisms for regulating transcription, and could be affected by environmental factors (17) . It is also known to be a critical mediator between the genome and the environment. A cytosine-phosphate-guanine (CpG) dinucleotide is a potential DNA methylation site (18) . DNA methylation mostly occurs at a cytosine in these CpG dinucleotides. Since increased methylation in the promoter is associated with decreased transcription, promoter SNPs that affect the CpG sequences could affect gene expression (19) . DNA methylation has been shown to affect the pathogenesis of T2D such as insulin secretion and insulin resistance (20) (21) (22) .
CpG-SNP is a SNP that affects the CpG sequence. Recent studies have shown that CpG-SNPs are associated with differential methylation and that this can affect the expression of nearby genes (23, 24) . SNP-420 is a CpG-SNP (Supplemental Fig. 1 ). Therefore, methylation at SNP-420 could affect the expression of RETN and plasma resistin in addition to a specific transcription factor that binds at SNP-420.
In view of this, to examine whether methylation at SNP-420 affects the expression of RETN and plasma levels, we analyzed the relation between methylation at SNP-420 and plasma resistin in 2078 subjects in the general Japanese population. We also analyzed the relation between the extent of methylation at SNP-420 and clinical parameters such as hs-CRP, which have previously been reported to be associated with plasma resistin (4) . Methylation at SNP-420 was found to be inversely associated with plasma resistin.
Methods

Ethics statement
All subjects were informed of the purpose of the study and their written consent was obtained. The study was approved by the ethics committee of the Ehime University Graduate School of Medicine.
Subjects
This study included 2078 community-dwelling Japanese subjects who were attending an annual medical check-up in a rural town located in Ehime prefecture in Japan (6) . The baseline clinical characteristics of the subjects were obtained from personal health records evaluated during their medical check-up. The clinical characteristics of these subjects [male/ female = 914/1164, age 62 6 13, body mass index (BMI) 23.4 6 3.2] from the previous paper are summarized in Supplemental Table 1 
Methylation analysis
Genomic DNA was extracted from peripheral white blood cells using a QIAamp DNA blood kit (QIAGEN GmbH, Hilden, Germany), or from THP-1 human monocytes using QIAamp DNA blood mini kit. Quantification of the methylation was performed by pyrosequencing after the bisulfite conversion of DNA. Bisulfite conversion involved the use of an EpiTect Bisulfite kit (QIAGEN) using 200 ng genomic DNA following the manufacturer's recommendations. The Bisulfite-converted DNA was amplified by polymerase chain reaction (PCR) using a PyroMark PCR kit (QIAGEN). The PCR primers and sequencing primers were designed using the PyroMark Assay Design Software Version 2.0 (QIAGEN). The sequences of the PCR primers and sequencing primers were AAACCTTCC-CACTTCCAACAA (reverse PCR primer), AGTTTTTGG-TATTATTTTTGGGGTAT (5 0 biotinylated forward PCR primer), and CTTCCAACAAAACCTCC (sequencing primer). Pyrosequencing of the biotinated PCR products was run on a PyroMark Q24 (QIAGEN) using PyroMark Gold Q96 reagents (QIAGEN) according to the manufacturer's instructions. 
Measurement of plasma resistin
Fasting plasma resistin was determined using a human resistin enzyme-linked immunosorbent assay kit (LINCO Research Inc., St. Charles, MO), according to the manufacturer's protocol, as described previously (3). The assay was linear below 0.16 ng/mL. Inter-and intra-assay coefficients of variation were 6.9 and 1.7% (low levels) and 7.2 and 8.1% (high levels), respectively.
Cell culture and treatment
The human monocytic cell line, THP-1, was purchased from JCRB (Osaka, Japan) and was cultured in RPMI 1640 medium (Life Technologies, Paisley, UK) supplemented with 10% fetal bovine serum. THP-1 human monocytes were treated with 0.03, 0.1, 0.3, or 1.0 mM 5-aza-2'-deoxycytidine (5-aza-dC; Merck Millipore, Billerica, MA) for 4 days.
Measurement of RETN mRNA
Total RNA was isolated from THP-1 cells using an RNeasy Mini Kit (QIAGEN Hilden, Germany). RETN messenger RNA (mRNA) was quantified by real-time PCR. First-strand complementary DNA was synthesized from 0.5 mg of total RNA using the High-Capacity Complementary DNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Realtime PCR was performed using 12.5 mL of Taqman ® Universal Master Mix (Applied Biosystems), 1 mL of Taqman ® Gene Expression Assays (Applied Biosystems), and RNase-free water to a final volume of 25 mL. PCR amplification was performed in an ABI 7500 Real Time PCR System (Applied Biosystems) with the following cycle conditions (initial cycle: 50°C for 2 minutes, initial denaturation 95°C for 10 minutes, 40 cycles of denaturation 95°C for 15 seconds, and annealing/extension of 60°C for 1 minute). Relative RNA levels were calculated by the 2 -ddCt method using 18S ribosomal RNA as the internal control. The primers, 18S ribosomal RNA (Hs99999901_s1) and RETN (Hs00220767_m1), were purchased from Applied Biosystems and used for real-time PCR.
Statistical analyses
Values are expressed as the mean 6 standard deviation (SD). Differences in methylation levels at SNP-420 and RETN mRNA in THP-1 cells were assessed by analysis of variance. Simple linear regression analyses were used to examine the association between the variables. To assess isolated effects of methylation at SNP-420 on plasma resistin, multiple regression analyses involving plasma resistin (ng/mL) as a dependent variable, and methylation at SNP-420 (%), age (year), sex (male = 1, female = 0), BMI, and hs-CRP (mg/dL) or SNP-420 genotypes as independent variables, were performed. To assess isolated effects of environmental factors on the extent of methylation at SNP-420, multiple regression analyses involving the extent of methylation at SNP-420 (%) as a dependent variable, and age (year), sex (male = 1, female = 0), BMI, hs-CRP (mg/dL), homeostasis model assessment of insulin resistance (HOMA-IR), plasma glucose (mg/dL), serum triglycerides (mg/dL), and serum total cholesterol (mg/dL) as independent variables were performed. Each of the SNP-420 genotypes, C/C, C/G, and G/G, are denoted by 2 dummy variables (c1, c2) = (0, 0), (1, 0) , and (0, 1), respectively, for all the analyses above. To assess isolated effects of resistin SNP on methylation at SNP-420, multiple regression analyses were performed involving methylation at SNP-420 (%) as a dependent variable, and age (year), sex (male = 1, female = 0), BMI, and each of SNPs [SNP-1093 (rs3760678), SNP-537 (rs34124816), SNP-420, SNP-358 (rs3219175), SNP+157 (rs3219177), SNP+299 (rs3745367), SNP+1263 (rs3745369)] genotypes in additive model (A/A = 0, a/A = 1, a/a = 2) as independent variables.
These analyses were performed using a commercially available statistical software package (JMP version 7.0, SAS Institute, Cary, NC). Methylation at SNP-420 for each haplotype defined by SNP-420 and SNP+1263 was estimated using SNPstats (25) .
Results
SNP-420 is a CpG-SNP
The DNA sequence in the vicinity of RETN SNP-420 (C.G) is shown in Supplemental Figure 1 . When SNP-420 (C.G) is a C, the sequence around SNP-420, 5 0 -AAGACGGAG-3 0 , contains a CpG site, which can potentially be methylated. When SNP-420 (C.G) is a G, the CpG site is abrogated in the sequence, 5 0 -AAGAGGGAG-3 0 . SNP-420 could alter this CpG site, the DNA methylation site, in the RETN promoter region.
A demethylation reagent, 5-aza-dC, decreased the methylation at SNP-420 and increased RETN mRNA in THP-1 human monocytes
To determine whether methylation at SNP-420 affects RETN expression, we first examined the effect of a demethylating reagent, 5-aza-dC, on the methylation at SNP-420 and RETN mRNA in THP-1 human monocytes, which carried only the C/C genotype of SNP-420 intrinsically. The 5-aza-dC caused a dose-dependent decrease in the extent of methylation at SNP-420 [ Fig. 1(A) ]. Conversely, this reagent caused an increase in RETN mRNA [ Fig. 1(B) ]. When all of the data from various concentrations of 5-aza-dC were combined, an inverse association between methylation at SNP-420 and RETN mRNA was found [b = -0.0566, P , 0.0001; Fig. 1(C) ]. Therefore, RETN mRNA was inversely associated with the extent of methylation at SNP-420.
Plasma resistin was inversely associated with methylation at SNP-420 mainly dependent on SNP-420 genotypes in the general Japanese population
To determine whether methylation at SNP-420 was associated with plasma resistin in vivo, we analyzed this in 2078 Japanese subjects (Supplemental Table 1 ). The methylation (%) at SNP-420 ranged from 1% to 56%, suggesting that this methylation was variable. When genotypes were not taken into consideration, methylation at SNP-420 was inversely associated with plasma resistin [b = -0.288, P , 0.0001; Fig. 2(A) ]. There also appear to be 3 groups divided by the range of methylation at SNP-420. When the number of subjects was assessed with respect to methylation (%) at SNP-420 in each 2% range, there appeared to be 3 peaks corresponding to 3 genotypes of SNP-420 [ Fig. 2(B) ]. Methylation at SNP-420 was highest in the C/C genotype (36.9 6 5.7%), followed by C/G (21.4 6 3.5%) , and G/G (2.9 6 1.4%). The extent of methylation at this site of the nonmethylated control DNA (EpiTect PCR Control DNA Set; QIAGEN) was 3.0 6 1.3% (n= 162). Because no significant difference was found between the extent of methylation in the G/G genotype and the nonmethylated control (P = 0.41), the methylation observed in the case of the G/G genotype could be an artifact produced during the bisulfite pyrosequencing. Therefore, the extent of methylation at SNP-420 was inversely associated with plasma resistin in the general Japanese population, and this association appears to be mainly dependent on SNP-420 genotypes.
Plasma resistin was inversely associated with methylation at SNP-420 in either C/C or C/G genotype of SNP-420
To determine whether methylation at SNP-420 was also associated with plasma resistin partially independent of SNP-420 genotypes, we analyzed these relations in each of SNP-420 genotypes. First, we analyzed plasma resistin by dividing into 2 groups according to the median value for the extent of methylation (%) at SNP-420 (low methylation group and high methylation group) in either C/C or C/G of the SNP-420 genotypes (Fig. 3) . Plasma resistin was higher in the subjects with a lower extent of methylation in both C/C and C/G genotypes (C/C genotype, low methylation 8.86 6 3.34 ng/mL, high methylation 7.44 6 2.69 ng/mL, P = 0.0012; C/G genotype, low methylation 14.22 6 7.00 ng/mL, high methylation 12.34 6 5.78 ng/mL, P , 0.001, respectively).
We next assessed the relation between plasma resistin and the extent of methylation at SNP-420 in each of SNP-420 genotypes using multiple regression analyses (Table 1 ). In each of the C/C and C/G genotypes, the extent of methylation at SNP-420 was found to be inversely associated with plasma resistin, after adjustment for age, sex, and BMI [C/C genotype, standardized regression coefficient (b) = -0.267, P , 0.001; C/G genotype, b = -0.171, P , 0.001; Model 1] . No association was found in the G/G genotype. When hs-CRP was further adjusted, these findings were essentially the same (Model 2). Furthermore, when all the subjects were analyzed together adjusted for age, sex, hs-CRP, BMI, and SNP-420 genotypes, the extent of methylation at SNP-420 was found to be inversely associated with plasma resistin (b = -0.348, P , 0.0001). Therefore, the extent of methylation at SNP-420 was inversely associated with plasma resistin also partially independent of the SNP-420 genotypes.
SNP+1263 G > C in the 3
0 untranslated region of RETN was also responsible for the methylation at SNP-420
To determine whether methylation at SNP-420 was associated with surrounding SNPs, we performed multiple regression analyses involving the extent of methylation at SNP-420 as a dependent variable, and each of SNPs around RETN [SNP-1093 (rsrs3760678), SNP-537 (rs34124816), SNP-420, SNP-358 (rs3219175), SNP+157 (rs3219177), SNP+299 (rs3745367), SNP+1263 (rs3745369)] as independent variables, adjusted for age, sex, and BMI (Supplemental Table 2 ). SNP-420 and SNP+1263 were found to be independently associated with the extent of methylation at SNP-420 (b = 0.918, P , 0.001; and b = -0.004, P , 0.001, respectively).
We next examined the relation between the methylation at SNP-420 and haplotypes defined by SNP-420 and SNP+1263 in this order (Supplemental Table 3 ). The effect of SNP+1263 on the methylation at SNP-420 could be assessed by comparing differences between the C-C and the C-G haplotype, because both haplotypes have a C at position -420, a possible methylation site. The C-C haplotype conferred a lower methylation at SNP-420 than the reference haplotype, C-G (-0.78%, P = 0.00021). Since the G-G haplotype and the G-C haplotype did not have a C at -420, they showed substantially no methylation at SNP-420 as expected (-16.63% and -17.7% lower than reference C-G, respectively, where the average difference between C and G at -420 was estimated to be about 15%). Comparison of these 2 haplotypes appeared not to be appropriate for estimating the effect of SNP+1263 on the methylation. Therefore, in addition to SNP-420 itself, SNP+1263 in the 3 0 Figure 3 . Plasma resistin was inversely associated with methylation at SNP-420 in either C/C or C/G genotype of SNP-420. Plasma resistin in high and low methylation groups in each of SNP-420 genotypes is shown. High and low methylation was defined by the median of the methylation (%) at SNP-420. High, more than the median of methylation (%). Low, equal, or less than the median of methylation (%). The number of subjects is shown at the bottom of the panel. Values are expressed as the mean 6 SD. Differences were assessed by analysis of variance (P , 0.001). Tukey-Kramer HSD test was used in post hoc analyses. *P = 0.0012; †P , 0.001. untranslated region of RETN, was also found to be responsible for the methylation at SNP-420.
Methylation at SNP-420 was associated with hs-CRP and BMI
To determine whether methylation at SNP-420 was associated with environmental factors, we next assessed that relation with clinical parameters. We performed multiple regression analyses involving the extent of methylation at SNP-420 as a dependent variable, and age, sex, BMI, hs-CRP, HOMA-IR, plasma glucose, serum triglycerides, and total cholesterol as independent variables in each of the SNP-420 genotypes (Table 2 ). Hs-CRP was found to be inversely associated with the extent of methylation at SNP-420 in the C/C or C/G genotype (b = -0.136, P , 0.001, and b = -0.125, P = 0.001, respectively). BMI was positively associated with methylation in the C/C genotype of SNP-420 (b = 0.184, P , 0.001; Table 2 ). HOMA-IR (b = -0.102, P = 0.01) and triglycerides (b = 0.076, P = 0.035) appeared to be associated with methylation at SNP-420 in C/C genotype. After Bonferroni's correction (raw P value 3 9), hs-CRP and BMI but not HOMA-IR or triglycerides remained significant for an association with the extent of methylation. Even when plasma resistin was further adjusted, these findings in the case of hs-CRP and BMI with methylation were essentially the same. Age was not also associated with the extent of methylation at SNP-420 in the C/C or C/G genotype. Therefore, the methylation at SNP-420 could be Multiple regression analyses involving methylation (%) at SNP-420 as a dependent variable were performed in each of the SNP-420 genotypes. b represents the standardized regression coefficient. Model 1: BMI, HOMA-IR, hs-CRP, PG, T-Cho, and TG were involved as independent variables adjusted for age and sex. Model 2: Plasma resistin levels were also included as an independent variable in addition to Model 1.
Abbreviations: T-Cho, total cholesterol; TG, triglyceride. a P values remained significant after Bonferonni's correction (raw P value 39). Multiple regression analyses involving plasma resistin as a dependent variable were performed in each of the SNP-420 genotypes. Model 1: Age, sex, BMI, and methylation (%) were involved as independent variables. Model 2: Hs-CRP was also included as an independent variable in addition to Model 1. b 0 represents the unstandardized regression coefficient; b represents the standardized regression coefficient.
doi: 10.1210/jc.2016-2417 press.endocrine.org/journal/jcemassociated with some environmental factors such as hs-CRP and BMI.
Discussion
In the current study, methylation at SNP-420 was found to be inversely associated with plasma resistin in 2078 subjects of the general Japanese population. When assessed in each of SNP-420 genotypes, plasma resistin was inversely associated with the extent of methylation at SNP-420 in the C/C or C/G genotype. In THP-1 human monocytes, 5-aza-dC resulted in a decrease in methylation at SNP-420, whereas RETN mRNA was increased.
In addition to SNP-420 affecting its own CpG sequence, SNP+1263 was also responsible for the methylation at SNP-420. Potential environmental factors, hs-CRP and BMI, were also associated with the extent of methylation at SNP-420.
We quantitated the extent of methylation at SNP-420 using genomic DNA from peripheral white blood cells, because resistin is expressed in white blood cells, mainly in monocytes, in peripheral blood in humans. In fact, methylation at SNP-420 in DNA from peripheral white blood cells was found to be positively correlated with that from isolated monocytes (r = 0.935, P , 0.001; Supplemental Fig. 2 ). An analysis of methylation at SNP-420 in DNA from peripheral white blood cells is worthwhile for the analysis in the relevant tissue, monocytes.
We have shown that SNP-420 functions as a CpG-SNP. Changes in methylation of a CpG-SNP could influence the expression of its target gene by affecting the binding of certain proteins to the DNA sequence including the SNP itself (26) . In fact, it was reported that the expression of the respiratory component NDUFB6 gene was associated with the methylation of a CpG-SNP near the gene (27) . A more recent study reported that, of the 40 T2D-associated SNPs identified by genome-wide association studies, 19 SNPs were CpG-SNPs (24) . Sixteen SNPs of these 19 CpG-SNPs were found to be associated with their methylation. SNP-420 could affect the expression of RETN and plasma resistin by acting as a CpG-SNP, leading to the susceptibility of T2D.
We found that methylation at SNP-420 was inversely associated with plasma resistin. We previously reported that plasma resistin was positively correlated with the number of G alleles at SNP-420 via the specific binding of transcription factors, Sp1/3 (3). In the current study, we have shown that the extent of methylation at SNP-420 was inversely associated with the number of G alleles at SNP-420. Therefore, the extent of methylation at SNP-420 was inversely associated with plasma resistin, mainly dependent on SNP-420 genotypes. When assessed in each of SNP-420 genotypes, the extent of methylation of the SNP-420 was inversely associated with plasma resistin in each of the C/C and C/G genotypes. This suggests that methylation at SNP-420 affects plasma resistin also partially independent of the SNP-420 genotype. In fact, we found that demethylation at SNP-420 was associated with an increased level of RETN mRNA in THP-1 human monocytes, whereas demethylation at other sites could also have some effects. Effects of DNA methylation on plasma resistin could be through changes in the binding of transcription factors to DNA sequences including the methylation site. Genetic and epigenetic factors (DNA methylation) could interact at SNP-420, thus determining plasma resistin and the expression of RETN.
The methylation at SNP-420 was also associated with SNP+1263 in the 3 0 untranslated region of RETN, which is located 1.7 kb downstream from SNP-420. The haplotype defined by SNP-420 and SNP+1263 also affected the extent of methylation at SNP-420. It has been reported that genetic variants could affect DNA methylation at various sites (28) (29) (30) (31) (32) (33) . In the quantitative trait loci (QTL) analyses for the CpG methylation across the genome, there were a number of QTLs, and the majority of these QTLs were in relatively close proximity to the methylation sites (31, 32) . It was also reported that individual QTLs affecting both the level of a transcript and a close methylation site are quite rare. We previously reported that plasma resistin was also associated with SNP+1263 as well as SNP-420 in the same population as the current study (6) . Therefore, SNP+1263 could be a rare causal SNP that affects both methylation and the expression of RETN. Since SNP-420 and SNP+1263 were in weak linkage disequilibrium (r 2 = 0.16, D 0 = 0.15) (6), the effect of SNP+1263 on the methylation at SNP-420 did not appear to be reflective of linkage disequilibrium. The binding of certain types of factors on the SNP+1263 or conformational change by genotypes of SNP+1263 could affect the extent of methylation at SNP-420. The precise mechanism underlying the effect of SNP+1263 on methylation at SNP-420 remains to be elucidated.
In the current study, no association was found between the extent of methylation at SNP-420 and SNP-358 genotype (Supplemental Table 2 ), although SNP-420 and SNP-358 were in tight linkage disequilibrium (r 2 = 0.50, D 0 = 0.99) (6). We previously reported that A at SNP-358 is required for G at SNP-420 to confer the highest plasma resistin (6) . This regulatory effect of SNP-358 on RETN expression could be exerted through a mechanism different from the methylation at SNP-420.
Methylation at SNP-420 was found to be inversely associated with plasma hs-CRP in C/C or C/G genotype.
Hs-CRP, reflective of low grade systemic inflammation, is elevated in inflammation-related diseases such as atherosclerosis (34) . While plasma CRP is associated with genetic variants, it is also under epigenetic controls (35, 36) . We previously reported that hs-CRP was positively associated with plasma resistin in the same population as the current study (4) . Other groups have also reported such a correlation (37, 38) . Methylation at SNP-420 could affect plasma resistin, but the extent of methylation at SNP-420 appears to be associated with hs-CRP partially independent of plasma resistin ( Table 2 , Model 2). Therefore, hs-CRP could be a possible environmental factor affecting methylation at SNP-420, thus influencing plasma resistin.
Methylation at SNP-420 was positively associated with BMI in the C/C genotype of SNP-420. Obesity has been reported to be associated with the methylation of UBASH3A and TRIM3 from peripheral blood leukocytes (39) . More recently, as the results of genome-wide analysis, it was reported that increased BMI was associated with increased methylation at the HIF3A locus and that the extent of the methylation was associated with 2 SNPs upstream from the gene (40) . These SNPs were not associated with BMI independently, suggesting that increased methylation at HIF3A could be the result of increased BMI. Likewise, the genotype of SNP-420 was not associated with BMI in the same population as the current study (4) . BMI could be a potential environmental factor affecting methylation at SNP-420.
In summary, plasma resistin was found to be inversely associated with the extent of methylation at SNP-420 mainly dependent on the SNP-420 genotype. The association was also explained partially independent of SNP-420 genotypes. Methylation at SNP-420 was also associated with genotypes of SNP+1263, plasma hs-CRP, and BMI. Therefore, SNP-420 could have dual, genetic and epigenetic, effects on plasma resistin. The underlying mechanism responsible for these findings including the specific effect of methylation at SNP-420 in vitro, and the relevance of methylation at SNP-420 in diabetes remain unknown. Further studies will be required to clarify these points.
